A Computer-Aided System for Determining the Application Range of a Warfarin Clinical Dosing Algorithm Using Support Vector Machines with a Polynomial Kernel Function

Determining the optimal initial dose for warfarin is a critically important task. Several factors have an impact on the therapeutic dose for individual patients, such as patients’ physical attributes (Age, Height, etc medication profile, co-morbidities, and metabolic genotypes (CYP2C9 and VKORCI). These wide range factors influencing therapeutic dose, create a complex environment for clinicians to determine the optimal initial dose. Using a sample of 4,237 patients, we have proposed a companion classification model to one of the most popular dosing algorithms (International Warfarin Pharmacogenetics Consortium (IWPC) clinical model), which identifies the appropriate cohort of patients for applying this model. The proposed model functions as a clinical decision support system that assists clinicians in dosing. We have developed a classification model using Support Vector Machines, with a polynomial kernel function to determine if applying the dose prediction model is appropriate for a given patient. The IWPC clinical model will only be used if the patient is classified as "Safe for model". By using the proposed methodology, the dosing model’s prediction accuracy increases by 15% in terms of Root Mean Squared Error and 17% in terms of Mean Absolute Error in dose estimates of patients classified as "Safe for model".

[1]  Lesley G Mitchell,et al.  In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. , 2010, Blood.

[2]  S. Shaughnessy,et al.  Do No Harm: Health Systems’ Duty to Promote Clinician Well-Being , 2022, American Journal of Hospital Medicine.

[3]  Bin Jiang,et al.  Evolutionary Ensemble Learning Algorithm to Modeling of Warfarin Dose Prediction for Chinese , 2019, IEEE Journal of Biomedical and Health Informatics.

[4]  Vladimir Vapnik,et al.  Statistical learning theory , 1998 .

[5]  E. Merriman,et al.  Bleeding risk with dabigatran in the frail elderly. , 2012, The New England journal of medicine.

[6]  M Gent,et al.  Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Houshang Darabi,et al.  Machine learning based prediction of warfarin optimal dosing for African American patients , 2013, 2013 IEEE International Conference on Automation Science and Engineering (CASE).

[8]  F. Kamali,et al.  Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients , 2018, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[9]  Mohammad Karim Sohrabi,et al.  Multi-objective feature selection for warfarin dose prediction , 2017, Comput. Biol. Chem..

[10]  Stephen E Kimmel,et al.  Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. , 2008, Pharmacogenomics.

[11]  Christine W. Duarte,et al.  High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans , 2011, Bioinform..

[12]  M. Whirl‐Carrillo,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing , 2011, Clinical pharmacology and therapeutics.

[13]  C. Richards,et al.  Emergency hospitalizations for adverse drug events in older Americans. , 2011, The New England journal of medicine.

[14]  M. Pirmohamed,et al.  Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. , 2009, Pharmacogenomics.

[15]  Jean-Louis Golmard,et al.  Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. , 2012, Blood.

[16]  F. Kamali,et al.  VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. , 2012, Blood.

[17]  A. Thompson,et al.  Genetic and Clinical Determinants Influencing Warfarin Dosing in Children With Heart Disease , 2013, Pediatric Cardiology.

[18]  Tugba Taskaya-Temizel,et al.  A Bayesian Estimation Framework for Pharmacogenomics Driven Warfarin Dosing: A Comparative Study , 2015, IEEE Journal of Biomedical and Health Informatics.

[19]  Jeffrey L. Anderson,et al.  Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial , 2010, Trials.

[20]  J. de Lemos,et al.  Emergency hospitalizations for adverse drug events. , 2012, The New England journal of medicine.

[21]  Houshang Darabi,et al.  A New Approach towards Minimizing the Risk of Misdosing Warfarin Initiation Doses , 2018, Comput. Math. Methods Medicine.

[22]  L. Cavallari,et al.  Warfarin Pharmacogenetics: To Genotype or Not to Genotype, That Is the Question , 2014, Clinical pharmacology and therapeutics.

[23]  Stuart A Scott,et al.  Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing? , 2014, Pharmacogenomics.

[24]  Houshang Darabi,et al.  Revisiting Warfarin Dosing Using Machine Learning Techniques , 2015, Comput. Math. Methods Medicine.

[25]  Masato Taguchi,et al.  Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. , 2011, Drug metabolism and pharmacokinetics.

[26]  J N Douglas,et al.  Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans , 2013, The Pharmacogenomics Journal.

[27]  M. Rieder,et al.  Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.

[28]  Yuchiao Chang,et al.  Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. , 2003, The New England journal of medicine.

[29]  Valentin Fuster,et al.  American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. , 2003, Circulation.

[30]  Mario Plebani,et al.  VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. , 2011, Pharmacogenomics.

[31]  Jie Chen,et al.  Warfarin maintenance dose Prediction for Patients undergoing heart valve replacement— a hybrid model with genetic algorithm and Back-Propagation neural network , 2018, Scientific Reports.

[32]  C. Thorn,et al.  Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans , 2008, Clinical pharmacology and therapeutics.